Legal & General Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-228,255
| Closed | -$9.18M | – | 3401 |
|
|
2026
Q1 | $9.18M | Buy |
228,255
+142,766
| +167% | +$3.08M | ﹤0.01% | 1162 |
|
|
2025
Q4 | $2.15M | Sell |
85,489
-6,903
| -7% | -$162K | ﹤0.01% | 1940 |
|
|
2025
Q3 | $2.09M | Sell |
92,392
-3,658
| -4% | -$85.3K | ﹤0.01% | 1959 |
|
|
2025
Q2 | $1.66M | Buy |
96,050
+16,980
| +21% | +$314K | ﹤0.01% | 2037 |
|
|
2025
Q1 | $1.73M | Sell |
79,070
-7,701
| -9% | -$213K | ﹤0.01% | 1982 |
|
|
2024
Q4 | $2.77M | Sell |
86,771
-1,192
| -1% | -$35.8K | ﹤0.01% | 1846 |
|
|
2024
Q3 | $2.54M | Sell |
87,963
-3,708
| -4% | -$137K | ﹤0.01% | 1875 |
|
|
2024
Q2 | $3.52M | Buy |
91,671
+5,827
| +7% | +$264K | ﹤0.01% | 1705 |
|
|
2024
Q1 | $5.05M | Buy |
85,844
+2,373
| +3% | +$151K | ﹤0.01% | 1512 |
|
|
2023
Q4 | $5M | Buy |
83,471
+1,693
| +2% | +$85.9K | ﹤0.01% | 1502 |
|
|
2023
Q3 | $3.11M | Sell |
81,778
-2,373
| -3% | -$104K | ﹤0.01% | 1688 |
|
|
2023
Q2 | $7.67M | Sell |
84,151
-2,517
| -3% | -$217K | ﹤0.01% | 1226 |
|
|
2023
Q1 | $5.72M | Buy |
86,668
+6,274
| +8% | +$362K | ﹤0.01% | 1350 |
|
|
2022
Q4 | $4.16M | Sell |
80,394
-248
| -0.3% | -$13.2K | ﹤0.01% | 1505 |
|
|
2022
Q3 | $5.51M | Sell |
80,642
-1,332
| -2% | -$78.8K | ﹤0.01% | 1326 |
|
|
2022
Q2 | $3.71M | Buy |
81,974
+11,617
| +17% | +$530K | ﹤0.01% | 1570 |
|
|
2022
Q1 | $3.58M | Buy |
70,357
+1,190
| +2% | +$52.5K | ﹤0.01% | 1705 |
|
|
2021
Q4 | $3.27M | Buy |
69,167
+11,268
| +19% | +$444K | ﹤0.01% | 1804 |
|
|
2021
Q3 | $1.91M | Buy |
57,899
+12,192
| +27% | +$685K | ﹤0.01% | 2045 |
|
|
2021
Q2 | $2.89M | Buy |
45,707
+610
| +1% | +$31.5K | ﹤0.01% | 1810 |
|
|
2021
Q1 | $1.94M | Sell |
45,097
-70
| -0.2% | -$3.31K | ﹤0.01% | 1993 |
|
|
2020
Q4 | $2.58M | Buy |
45,167
+5,037
| +13% | +$213K | ﹤0.01% | 1782 |
|
|
2020
Q3 | $1.21M | Buy |
40,130
+19,387
| +93% | +$579K | ﹤0.01% | 1966 |
|
|
2020
Q2 | $678K | Buy |
20,743
+9,136
| +79% | +$293K | ﹤0.01% | 2100 |
|
|
2020
Q1 | $329K | Sell |
11,607
-766
| -6% | -$27.2K | ﹤0.01% | 2175 |
|
|
2019
Q4 | $379K | Buy |
12,373
+1,897
| +18% | +$52.5K | ﹤0.01% | 2278 |
|
|
2019
Q3 | $252K | Hold |
10,476
| – | – | ﹤0.01% | 2307 |
|
|
2019
Q2 | $265K | Buy |
10,476
+2,247
| +27% | +$45.7K | ﹤0.01% | 2273 |
|
|
2019
Q1 | $161K | Buy |
8,229
+1,754
| +27% | +$27.6K | ﹤0.01% | 2371 |
|
|
2018
Q4 | $86K | Buy |
6,475
+437
| +7% | +$6.71K | ﹤0.01% | 2498 |
|
|
2018
Q3 | $108K | Buy |
6,038
+653
| +12% | +$12.1K | ﹤0.01% | 2490 |
|
|
2018
Q2 | $118K | Buy |
5,385
+3,503
| +186% | +$80.5K | ﹤0.01% | 2445 |
|
|
2018
Q1 | $42K | Hold |
1,882
| – | – | ﹤0.01% | 2830 |
|
|
2017
Q4 | $41K | Buy |
+1,882
| New | +$27.7K | ﹤0.01% | 2936 |
|
Other funds holding APLS
Legal & General Group's APLS Position: Q2 2026 in Review
Legal & General Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 228,255 shares — an estimated $9.18M sold.
Legal & General Group first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $9.18M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Legal & General Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Legal & General Group sold 228,255 Apellis Pharmaceuticals shares in Q2 2026, an estimated $9.18M.
- Legal & General Group first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Legal & General Group's Apellis Pharmaceuticals position peaked at $9.18M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.